The award incrementally de-risks the room-temperature-stable NexoBrid development program and extends MediWound's cash runway. Monitor for IND submission timing and any subsequent DoW contract modifications that could signal further funding or program expansion.
Price Chart
Executive Summary
MediWound received an additional $3.3 million from the U.S. Department of War to develop a room-temperature-stable formulation of NexoBrid for battlefield burn care, raising the total program budget to $21.8 million. The non-dilutive funding supports development through IND submission. This is a modest, incremental positive that extends a government-funded development program but does not change the company's near-term revenue or commercial outlook.
Key Financial Metrics
Key Facts
- MediWound awarded additional $3.3 million from U.S. Department of War for room-temperature-stable NexoBrid formulation.
- Total program budget raised to $21.8 million.
- Funding supports development through IND submission for battlefield burn care.
- Funding is non-dilutive.
- Program is within scope of existing North American license agreement with Vericel Corporation (Nasdaq: VCEL).
Financial Impact
$3.3 million additional non-dilutive funding; total program budget $21.8 million
Risk Factors
- Government contracts are subject to termination for convenience, budget sequestration, or changes in priorities.
- Development of room-temperature-stable formulation may face technical or regulatory delays.
- NexoBrid commercial rights in North America are held by Vericel, limiting MediWound's direct upside from this program.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3366127 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 22, 2026 5w ago | Press Release | $13.95 $13.80 | ▼ −1.08% | ▲ +0.11% | $12.55 (−10.04%) |
Jun 2, 2026 21w ago | Insider Cluster | $13.76 $14.30 | ▲ +3.92% | ▲ +6.89% | $12.55 (−8.79%) |
May 27, 2026 21w ago | Press Release | $14.33 $13.73 | ▲ +4.19% | ▲ +4.66% | $12.55 (+12.42%) |
May 7, 2026 24w ago | Press Release | $17.27 $16.25 | ▼ −5.91% | ▼ −7.41% | $12.55 (−27.33%) |
Mar 30, 2026 30w ago | 6-K | $16.11 $17.27 | ▲ +7.20% | ▲ +3.26% | $12.55 (−22.10%) |
Mar 5, 2026 33w ago | Press Release | $17.03 $16.58 | ▼ −2.64% | ▼ −1.11% | $12.55 (−26.31%) |
Mar 5, 2026 33w ago | Press Release | $17.45 $16.58 | ▲ +4.99% | ▲ +2.75% | $12.55 (+28.08%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers